The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The European Commission (EC) has approved nivolumab (Opdivo®) in combination with brentuximab vedotin for the treatment of adult and pediatric patients with relapsed or refractory classical Hodgkin Lymphoma (cHL). This indication applies to children ages 5 years and older, adolescents, and adults up to 30 years of age who have received one prior line of therapy.
The EBMT analysis was led by first author Anna Ossami Saidy of the Department of Hematology and Cell Therapy at Helios Klinikum Berlin-Buch in Germany.
Beyond this new indication, the drug is already approved in Brazil and the European Union for relapsed or refractory diffuse large B-cell lymphoma, according to the press release by Knight Therapeutics.
Analysis of the QuANTUM-First phase 3 trial found that the impact of quizartinib on patient-reported outcomes and health-related quality of life (QoL) were equivalent to a placebo, based on the European Organisation for Research and Treatment of Cancer 30-item Core QoL Questionnaire.
When multiple myeloma and chronic lymphocytic leukemia appear in the same patient, they do not derive from the same B-cell but rather develop independently from separate B-cells.
To access the SOHO Career Center click the following link.
